STOCK TITAN
  1. Home
  2. News
  3. PKI

PERKINELMER INC - PKI STOCK NEWS

Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.

PerkinElmer Inc. (symbol: PKI) is a leading global provider of solutions that enable scientists, researchers, and clinicians to tackle complex challenges in science and healthcare. The company's mission is to innovate for a healthier world through unique solutions that serve the diagnostics, life sciences, food, and applied markets.

PerkinElmer collaborates closely with its customers to deliver earlier and more accurate insights. This is supported by the company's deep market knowledge and technical expertise. With a dedicated workforce of approximately 14,000 employees worldwide, PerkinElmer is committed to improving the quality of life, creating healthier families, and sustaining the wellbeing and longevity of people globally.

In 2020, PerkinElmer reported revenues of approximately $3.8 billion and serves customers in 190 countries. Notably, the company is a component of the S&P 500 index, underscoring its significant market presence and financial stability.

Recent Achievements and Current Projects

  • Strategic partnerships with key industry players to enhance diagnostic solutions and life sciences research.
  • Continuous investment in innovative technologies and solutions that drive earlier and more accurate healthcare insights.
  • Expansion of global reach through new product launches tailored to various market needs.

PerkinElmer's commitment to innovation and collaboration makes it a crucial player in the healthcare and scientific research sectors. By leveraging its extensive expertise and comprehensive solutions, the company strives to address the most pressing challenges faced by its customers.

News

Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group

Rhea-AI Summary
Revvity, Inc. (RVTY) files a complaint against Cloud Software Group for breaching strategic partnership obligations related to Spotfire® software. Revvity reaffirms 2024 revenue guidance amidst legal dispute.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) introduces Signals ChemDraw, a cutting-edge chemistry suite enhancing research productivity and collaboration in chemical, pharmaceutical, and biotechnology industries. The software aims to streamline communication of complex chemical concepts, promote interdisciplinary cooperation, and boost research efficiency. Signals ChemDraw offers intuitive design, advanced features, and cloud-native architecture, catering to the evolving needs of the scientific community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Revvity to Present at Upcoming Investor Conferences

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) will present at several investor conferences in February and March 2024, providing updates on the company's strategic priorities. Key executives like Max Krakowiak and Prahlad Singh will discuss the financial and operational aspects at these events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) introduces Signals ClinicalTM, a centralized data science platform integrated with Spotfire for efficient clinical study data management, enabling quick clinical decisions and therapeutic advancements. The platform emphasizes cross-functional collaboration, customization, and scalability to enhance clinical research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) reported a 6% decline in fourth quarter revenue, with a GAAP EPS of $0.64 and adjusted EPS of $1.25. The full year 2023 saw a 17% decrease in revenue and a 59% decrease in GAAP EPS compared to 2022. The company initiated full year 2024 guidance of $2.79-$2.85 billion in revenue and adjusted EPS of $4.55-$4.75. The life sciences segment experienced an 8% decrease in revenue for Q4 2023, while the diagnostics segment saw a 4% decrease. The company's financial performance reflects a challenging year and uncertain future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) announced the election of Sophie Vandebroek and Michael Klobuchar to its board of directors, effective February 1, 2024. Vandebroek brings expertise in AI, business processes, sustainability, and cybersecurity, with a background in global organizations and academic advisory. Klobuchar, an executive at Merck & Co. Inc., has extensive experience in strategic and operational initiatives for global enterprises, M&A activities, and leadership in research and development. The company also expressed gratitude to Dr. Sylvie Gregoire for her service on the board since 2015.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
News

Revvity Board Declares Quarterly Dividend

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) has announced a regular quarterly dividend of $0.07 per share of common stock, payable on May 10, 2024, to shareholders of record at the close of business on April 19, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
News

Revvity to Hold Earnings Call on Thursday, February 1, 2024; Provides Update on Financial Performance

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) announces Q4 2023 financial results, including a revenue decline of -7% and -4% in organic revenue. Full year 2023 adjusted earnings per share expected to meet or exceed guidance. Prahlad Singh to present at J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Revvity to Present at J.P. Morgan Healthcare Conference

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) will present at the 42nd annual J.P. Morgan Healthcare Conference to provide an update on the Company and its strategic priorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News

Revvity to Present at Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) to Present at 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the market cap of PERKINELMER (PKI)?

The market cap of PERKINELMER (PKI) is approximately 14.5B.

What does PerkinElmer Inc. do?

PerkinElmer provides solutions that help scientists, researchers, and clinicians address challenges in diagnostics, life sciences, food, and applied markets.

What is the mission of PerkinElmer Inc.?

PerkinElmer's mission is to innovate for a healthier world.

How many employees does PerkinElmer Inc. have?

PerkinElmer has approximately 14,000 employees worldwide.

What was PerkinElmer Inc.'s revenue in 2020?

PerkinElmer reported revenues of approximately $3.8 billion in 2020.

In how many countries does PerkinElmer Inc. serve customers?

PerkinElmer serves customers in 190 countries.

What are some of PerkinElmer Inc.'s recent achievements?

Recent achievements include strategic partnerships, investment in innovative technologies, and global expansion through new product launches.

How does PerkinElmer Inc. contribute to healthcare?

PerkinElmer contributes by providing solutions that enable earlier and more accurate healthcare insights.

Is PerkinElmer Inc. part of any major stock index?

Yes, PerkinElmer is a component of the S&P 500 index.

What markets does PerkinElmer Inc. serve?

PerkinElmer serves diagnostics, life sciences, food, and applied markets.

What is a core focus of PerkinElmer Inc.'s partnerships?

PerkinElmer focuses on enabling earlier and more accurate insights through its partnerships.
Stock PKI logo
PERKINELMER INC

NYSE:PKI

PKI Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

PKI Stock Data

14.46B
109.03M
0.27%
86.26%
2.79%
Diagnostics & Research
Healthcare
Link
United States
Waltham